Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial
See more from Benzinga
AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate
Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.